Streetbeat News

Analyst Ratings

TMCI

Treace Medical Concepts (NASDAQ:TMCI) received 5 analyst ratings in the last quarter, with 4 being bullish and 1 indifferent. The average 12-month price target is $23.2, representing a 5.31% decrease from the previous target of $24.50. Analysts use various methods to forecast stock performance, and their ratings can influence market behavior.

Portfolio Pulse from Benzinga Insights

November 10, 2023 | 4:00 pm

HLMN

Hillman Solns (NASDAQ:HLMN) received 4 analyst ratings in the last quarter, with an average 12-month price target of $10.62, a decrease from the previous $11.12 target. Ratings are 1 bullish, 3 somewhat bullish, and no bearish ratings. The high target is $12.00 and the low is $9.50.

Portfolio Pulse from Benzinga Insights

November 10, 2023 | 4:00 pm

ATRA

Atara Biotherapeutics (NASDAQ:ATRA) has been rated by 4 analysts over the past 3 months, with 1 bullish, 1 indifferent, and 2 bearish ratings. The average 12-month price target is $7.72, a decrease of 35.67% from the previous target of $12.00. The high target is $28.00 and the low is $0.50. Analyst ratings are important as they provide investors with insights into stock performance based on research and financial analysis.

Portfolio Pulse from Benzinga Insights

November 10, 2023 | 4:00 pm

DCBO

Goldman Sachs analyst Kevin Kumar has maintained a Neutral rating on Docebo (NASDAQ:DCBO) and increased the price target from $39 to $44.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 3:59 pm

HLTH

Goldman Sachs analyst Matthew Sykes has maintained a Neutral rating on Cue Health (NASDAQ:HLTH) and reduced the price target from $0.75 to $0.5. This adjustment reflects a more conservative valuation of the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 3:58 pm

CCOI

Goldman Sachs analyst Brett Feldman has maintained a Neutral rating on Cogent Communications Holdings (NASDAQ:CCOI) and increased the price target from $60 to $67.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 3:58 pm

BIGC

Goldman Sachs analyst Gabriela Borges has maintained a Buy rating on BigCommerce Holdings (NASDAQ:BIGC) but reduced the price target from $13 to $11.5.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 3:57 pm

DBD

DA Davidson analyst Matthew Summerville has upgraded Diebold Nixdorf (NYSE:DBD) from Neutral to Buy and increased the price target from $25 to $29. This upgrade reflects a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 3:56 pm

BTCUSD

CME

Analyst Cory Mitchell predicts an 88% increase in Bitcoin's value, potentially reaching over $69,000 by mid-2024. This forecast is based on historical uptrends and current market dynamics, despite recent industry challenges. The growth is partly attributed to the anticipation of regulated Bitcoin ETFs in the U.S. and increased institutional interest, as evidenced by Bitcoin futures trading volumes on the CME surpassing those of Binance. The upcoming Benzinga's Future of Digital Assets conference will discuss these market trends.

Portfolio Pulse from Murtuza Merchant

November 10, 2023 | 3:55 pm

ATRA

Goldman Sachs analyst Tommie Reerink has maintained a Sell rating on Atara Biotherapeutics (NASDAQ:ATRA) and reduced the price target from $3 to $0.5.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 3:55 pm